Encodes An Enzyme Patents (Class 536/23.2)
  • Patent number: 9758831
    Abstract: Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: September 12, 2017
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat Achiron, Michael Gurevich
  • Patent number: 9738877
    Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: August 22, 2017
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Keith Bauer, Thomas W. Myers, Fred Reichert, Shawn Suko
  • Patent number: 9624500
    Abstract: The invention provides methods and compositions for modifying tocochromanol biosynthesis in plants. The present invention thus surprisingly and beneficially provides for increasing desired tocochromanol compounds in plants and enhancing the nutritional quality of human food and animal feed, without associate deleterious plant phenotypes.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: April 18, 2017
    Assignee: The Curators of the University of Missouri
    Inventors: Gary Stacey, Minviluz G. Stacey
  • Patent number: 9597391
    Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: March 21, 2017
    Assignee: HELMHOLTZ_ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
    Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
  • Patent number: 9593148
    Abstract: The present invention relates to non-competitive allosteric peptide inhibitors of DPP9 and/or DPP8, competitive peptides binding to SUMO1, nucleic acid molecules and expression vectors coding said peptide inhibitors, host cells expressing said inhibitors, kits comprising said inhibitors, as well as methods of producing said inhibitors, and uses of said peptide inhibitors; as further defined in the Claims.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 14, 2017
    Assignee: GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS
    Inventors: Ruth Geiss-Friedlander, Esther Pilla
  • Patent number: 9573982
    Abstract: The present invention provides modified tamabidin 2, which is a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2, an amino acid sequence having one or more amino acid mutations in the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having an identity of not less than 80% to the amino acid sequence of SEQ ID NO: 2 and having biotin-binding activity, wherein an asparagine residue at position 115 of SEQ ID NO: 2 is replaced with cysteine. The modified biotin-binding protein has remarkable heat resistance.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: February 21, 2017
    Assignee: JAPAN TOBACCO INC.
    Inventors: Yoshimitsu Takakura, Naomi Oka
  • Patent number: 9540678
    Abstract: The present invention intends to provide an assay system using split luciferase that has a remarkably high detection sensitivity. In an embodiment, binding of mutually binding first and second proteins is detected by preparing a first fusion protein comprising the first protein fused with a peptide having the amino acid sequence of amino acid SEQ ID NO: 1 and a second fusion protein comprising the second protein fused with a peptide having an amino acid sequence selected from the group consisting of amino acid SEQ ID NOS: 2 to 6, and allowing the first fusion protein to bind with the second fusion protein to form a complex, and detecting luminescence emitted from the complex.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: January 10, 2017
    Assignees: The University of Tokyo, Toyo Boseki Kabushiki Kaisha, ProbeX Inc.
    Inventors: Takeaki Ozawa, Naomi Misawa, Kenji Miura, Tasuku Okamoto, Shigeaki Nishii, Kenji Masuda
  • Patent number: 9513288
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: December 6, 2016
    Assignees: The United States of America as Represented by the Department of Veterans Affairs, University of Utah Research Foundation
    Inventor: Matthew A. Movsesian
  • Patent number: 9511119
    Abstract: Preparations containing hepatocyte growth factor (HGF) and hyaluronic acid (HA) and methods of making and using same. The HGF and HA preparations can be prepared together in solution as an injectable fluid without gelatinization, or impregnated within a porous hydrophilic matrix material with, or without, cross-linking of the HA with the matrix material. The preparations can be used as a dermal filler or to generate and promote healing of cartilage, vertebral discs, connective tissues such as tendons and ligaments and bone in vivo.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 6, 2016
    Assignee: NuTech Spine, Inc.
    Inventor: Howard P. Walthall, Jr.
  • Patent number: 9487768
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: November 8, 2016
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9474293
    Abstract: Transgenic plants that express CIVPS or intein modified proteins, compositions of matter comprising them, products of diverse applications made from the transgenic plants, methods to construct the transgenic plants containing CIVPS or intein modified genes, methods to express CIVPS or intein modified proteins in plants, and methods of using the transgenic plants.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: October 25, 2016
    Assignee: Agrivida, Inc.
    Inventor: R. Michael Raab
  • Patent number: 9464285
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: October 11, 2016
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9393323
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: July 19, 2016
    Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
  • Patent number: 9387192
    Abstract: The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: July 12, 2016
    Assignee: DKFZ DEUTCHERS KREBSFORSCHUNGSZENTRUM
    Inventors: Min Li-Weber, Peter H. Krammer
  • Patent number: 9309501
    Abstract: Isolated DNA polymerase and the mutant DNA polymerases thereof are provided. The DNA polymerases have good thermostability.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: April 12, 2016
    Assignee: Industrial Technology Research Institute
    Inventors: Tseng-Huang Liu, Pei-Shin Jiang, Chih-Lung Lin, Su-Jan Lee, Chao-Hung Kao
  • Patent number: 9297028
    Abstract: Methods for the fermentive production of four carbon alcohols is provided. Specifically, butanol, preferably 1-butanol is produced by the fermentive growth of a recombinant bacterium expressing a 1-butanol biosynthetic pathway.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: March 29, 2016
    Assignee: Butamax Advanced Biofuels LLC
    Inventors: Gail K. Donaldson, Lixuan Lisa Huang, Lori Ann Maggio-Hall, Vasantha Nagarajan, Charles E. Nakamura, Wonchul Suh
  • Patent number: 9273100
    Abstract: The present invention relates to compositions and methods comprising genes and peptides associated with cyclic peptides and cyclic peptide production in mushrooms. In particular, the present invention relates to using genes and proteins from Galerina species encoding peptides specifically relating to amatoxins in addition to proteins involved with processing cyclic peptide toxins. In a preferred embodiment, the present invention also relates to methods for making small peptides and small cyclic peptides including peptides similar to amanitin. Further, the present inventions relate to providing kits for making small peptides.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: March 1, 2016
    Assignee: Board of Trustees of Michigan State University
    Inventors: Heather E. Hallen-Adams, John S. Scott-Craig, Jonathan D. Walton, Hong Luo
  • Patent number: 9273104
    Abstract: The present invention relates to methods for producing a polypeptide having biological activity, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a first polynucleotide encoding the polypeptide operably linked to a second polynucleotide encoding a variant signal peptide or a variant prepropeptide; and (b) isolating the secreted polypeptide having biological activity from the cultivation medium.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: March 1, 2016
    Assignees: NOVOZYMES, INC., NOVOZYMES A/S
    Inventors: Mads Bjornvad, Debbie Yaver
  • Patent number: 9260729
    Abstract: The invention provides a non-naturally occurring microbial organism having at least one exogenous gene insertion and/or one or more gene disruptions that confer production of primary alcohols. A method for producing long chain alcohols includes culturing these non-naturally occurring microbial organisms.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: February 16, 2016
    Assignee: Genomatica, Inc.
    Inventors: Jun Sun, Priti Pharkya, Anthony P. Burgard
  • Patent number: 9212361
    Abstract: The present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing hypertension in a subject in need thereof.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: December 15, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot (Paris VII), Universite Paris Descartes
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus
  • Patent number: 9212371
    Abstract: The present invention pertains to the recombinant manufacture of polyunsaturated fatty acids. Specifically, it relates to acyltransferase polypeptides, polynucleotides encoding said acyltransferases as well as vectors, host cells, non-human transgenic organisms containing said polynucleotides. Moreover, the present invention contemplates methods for the manufacture of polyunsaturated fatty acids as well as oils obtained by such methods.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: December 15, 2015
    Assignee: BASF Plant Science Company GmbH
    Inventors: Toralf Senger, Sten Stymne, Jenny Lindberg Yilmaz
  • Patent number: 9187736
    Abstract: Transgenic soybean seed having increased total fatty acid content of at least 10% and altered fatty acid profiles when compared to the total fatty acid content of non-transgenic, null segregant soybean seed are described. DGAT genes from oleaginous organisms are used to achieve the increase in seed storage lipids.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: November 17, 2015
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Knut Meyer, Howard Glenn Damude, Kevin G. Ripp, Kevin L. Stecca
  • Patent number: 9180149
    Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: November 10, 2015
    Assignee: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: David Kirn
  • Patent number: 9181555
    Abstract: An isolated polypeptide comprising a hydrogen generating enzyme attached to a heterologous ferredoxin is disclosed, as well as polynucleotides encoding same, nucleic acid constructs capable of expressing same and cells expressing same. A method for generating hydrogen using the isolated polypeptide is also disclosed.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: November 10, 2015
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Iftach Yacoby, Ehud Gazit, Nathan Nelson, Itai Benhar
  • Patent number: 9175274
    Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: November 3, 2015
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Wenchao Yang
  • Patent number: 9175299
    Abstract: The present invention is directed to nucleic acids encoding polypeptides that confer upon a plant tolerance to an imidazolinone and/or other acetohydroxyacid synthase (AHAS) inhibiting herbicide when expressed in the plant. The present invention also provides plants having increased tolerance to an imidazolinone and/or other AHAS-inhibiting herbicide. More particularly, the present invention includes plants containing at least one IMI nucleic acid. The present invention also includes seeds produced by these plants and methods of controlling weeds in the vicinity of these wheat plants.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: November 3, 2015
    Assignee: BASF AGROCHEMICAL PRODUCTS, B.V.
    Inventors: John Moffatt, Rob Bruns, Iwona Birk, Bijay Singh
  • Patent number: 9120871
    Abstract: Expression of FGF21 in a S. cerevisiae pmt2 knock out strain reduces the O-glycosylation significantly and does not decrease the expression level. Expression in mkc7 knock out strain can decrease degradation of FGF21 and analogues thereof. Point mutations at position R17 and R36 can decrease degradation of FGF21 and analogues thereof when they are expressed in yeast.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: September 1, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Rita Slaaby, Inger Lautrup-Larsen
  • Patent number: 9074224
    Abstract: Disclosed herein are methods and compositions for gene targeting utilizing fusion molecules comprising a recombinase domain and a sequence-specific DNA-binding domain.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: July 7, 2015
    Assignee: Recombinetics, Inc.
    Inventors: Jeffrey J. Essner, Hsin-Kai Liao, Scott C. Fahrenkrug
  • Publication number: 20150147365
    Abstract: The present invention relates to an oral composition comprising a volatile sulphur compound breath-odour controlling amount of methyl mercaptan oxidase. The oral composition may be used in a method for controlling breath-odour in a host, which method comprises applying the composition to the oral cavity of that host. The invention also provides a polypeptide having methyl mercaptan oxidase activity, wherein said polypeptide is: (a) a polypeptide comprising an amino acid sequence as set out in SEQ ID NO: 2; (b) a polypeptide comprising an amino acid sequence having at least 50% sequence identity with the amino acid sequence of SEQ ID NO: 2; (c) a polypeptide encoded by a polynucleotide comprising the polynucleotide sequence as set out in SEQ ID NO: 1 or SEQ ID NO: 3; or (d) a fragment of a polypeptide as defined in (a), (b) or (c).
    Type: Application
    Filed: May 13, 2013
    Publication date: May 28, 2015
    Inventors: Luppo Edens, Evert Tjeerd Van Rij, Marco Jan Lambertus De Groot
  • Publication number: 20150147800
    Abstract: The present invention relates to a method for the enzymatic decarboxylation of malonic acid (propanedioic acid) derivatives catalyzed by enzymes structurally and/or functionally related to arylmalonate decarboxylase (AMDase) as isolated from microorganisms of the genus Bordetella. The present invention also relates to novel enzymes with a decarboxylase activity, useful for performing the claimed method, mutants thereof, corresponding coding sequences and expression systems, methods of preparing said novel enzymes, and screening methods for obtaining further suitable enzymes also having said decarboxylase activity.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 28, 2015
    Inventors: Bernhard Hauer, Nina Schneider, Krzysztof Okrasa, Jason Micklefield, David Leys, Colin Levy
  • Publication number: 20150150156
    Abstract: The present disclosure relates to recombinant methyltransferases that epigenetically silence gene expression and to methods of using such proteins for reducing the expression of genes in plants.
    Type: Application
    Filed: January 11, 2013
    Publication date: May 28, 2015
    Inventors: Steve E. Jacobsen, Elena Caro
  • Publication number: 20150150157
    Abstract: Prephenate dehydrogenases and arogenate dehydrogenase polynucleotide and polypeptide sequences are provided herein. These polypeptides are all insensitive to effector based feedback inhibition. Polypeptides with these activities and lacking feedback inhibition by the product were not previously identified and characterized from plants. The polypeptides may be used to generate constructs and transgenic cells or plants. Methods of increasing production of products of the tyrosine or HPP pathway by increasing expression of the polynucleotides provided herein in plants or cells overexpressing the polypeptides are provided. In addition overexpression of the polypeptides in plant cells increases resistance to herbicides.
    Type: Application
    Filed: November 19, 2014
    Publication date: May 28, 2015
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hiroshi A. Maeda, Craig Albert Schenck
  • Patent number: 9040269
    Abstract: A recombinant micro-organism producing resveratrol by a pathway in which phenylalanine ammonia lyase (PAL) produces trans-cinnamic acid from phenylalanine, cinnamate 4-hydroxylase (C4H) produces 4-coumaric acid from said trans-cinnamic acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA, or in which L-phenylalanine- or tyrosine-ammonia lyase (PAL/TAL) produces 4-coumaric acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA. The micro-organism may be a yeast, fungus or bacterium including Saccharomyces cerevisiae, E. coli, Lactococcus lactis, Aspergillus niger, or Aspergillus oryzae.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: May 26, 2015
    Assignee: Evola SA
    Inventors: Michael Katz, Hans Peter Smits, Jochen Förster, Jens Bredal Nielsen
  • Patent number: 9040278
    Abstract: An ?-amylase from Bacillus subtilis (AmyE) produces significant amounts of glucose from various carbohydrate substrates, including vegetable starch, maltoheptaose, and maltotriose. Among other things, this advantageous property allows AmyE or variants thereof to be used in a saccharification reaction having a reduced or eliminated requirement for glucoamylase. The reduction or elimination of the glucoamylase requirement significantly improves the efficiency of the production of ethanol or high fructose corn syrup, for example.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: May 26, 2015
    Assignee: DANISCO US INC.
    Inventors: Luis G. Cascao-Pereira, Regina Chin, William A. Cuevas, David A. Estell, Sang-Kyu Lee, Michael J. Pepsin, Scott D. Power, Sandra W. Ramer, Carol A. Requadt, Andrew Shaw, Amr R. Toppozada, Louise Wallace
  • Patent number: 9040279
    Abstract: The present disclosure relates to a Bacillus subtilis alpha-amylase (AmyE) or its variants thereof. AmyE or its variants thereof may be used to more efficiently produce fermentable sugars from starch. Also disclosed are a composition comprising a glucoamylase and AmyE or variant thereof and a method of processing starch utilizing the described enzyme composition.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: May 26, 2015
    Assignee: DANISCO US INC.
    Inventors: Suzanne Breneman, Sung Ho Lee, Vivek Sharma, Jayarama K. Shetty
  • Patent number: 9040238
    Abstract: The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) above.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: May 26, 2015
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN BERLIN-BUCH
    Inventors: Michael Gotthardt, Norbert Hübner, Marion Lewis Greaser, Wei Guo
  • Patent number: 9040262
    Abstract: The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: May 26, 2015
    Assignee: Codexis, Inc.
    Inventors: Michael Crowe, Oscar Alvizo, Behnaz Behrouzian, Yong Koy Bong, Steven J. Collier, Anupam Gohel, Jagadeesh Mavinahalli, Naga Modukuru, Emily Mundorff, Derek Smith, Shiwei Song, Wan Lin Yeo
  • Publication number: 20150140587
    Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate and has at least two amino acid substitutions relative to the wild-type hydrolase. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.
    Type: Application
    Filed: July 14, 2014
    Publication date: May 21, 2015
    Inventors: Aldis Darzins, Lance Encell, Tonny Johnson, Dieter Klaubert, Georgyi V. Los, Mark McDougall, Keith V. Wood, Monika G. Wood, Chad Zimprich
  • Publication number: 20150140132
    Abstract: The object of the present invention is to provide Humulus lupulus-derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. The present invention provides Humulus lupulus-derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. The present invention provides a transformant transformed with a gene for Humulus lupulus-derived monoterpene glycosyltransferase and a method for producing such a transformant.
    Type: Application
    Filed: February 5, 2013
    Publication date: May 21, 2015
    Inventors: Eiichiro Ono, Nobuo Tsuruoka
  • Publication number: 20150141633
    Abstract: The disclosure relates to a method for enhancing the biosynthesis and/or secretion of sapogenins in the culture medium of plant and microbial cell cultures. Further, the disclosure also relates to the identification of novel genes involved in the biosynthesis of sapogenin intermediates, as well as to novel sapogenin compounds.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 21, 2015
    Inventors: Alain Goossens, Tessa Moses, Jacob Pollier, Lorena Almagro Romero
  • Publication number: 20150141287
    Abstract: Genetic markers associated with intellectual disability as well as compositions, methods and kits for screening for genetic markers of intellectual disability, diagnosing intellectual disability and identifying individuals with a predisposition for offspring suffering from intellectual disability are provided.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 21, 2015
    Inventor: John B. Vincent
  • Publication number: 20150140169
    Abstract: The invention relates to a polypeptide having chymosin activity which: a. is capable of hydrolysing bovine alpha s1-casein at position F23F24 so as to form ?s1-I CN (f24-199) more rapidly than camel chymosin; and b. has a C/P ratio higher than the C/P ratio of bovine chymosin.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 21, 2015
    Inventors: Petrus Jacobus Theodorus Dekker, René Marcel De Jong, Michael Dennis Tabeling, Cornelis Marinus Muijlwijk
  • Publication number: 20150140641
    Abstract: The present invention relates to variant endoglucanases having improved thermoactivity, improved thermostability, and improved viscosity reduction activity over wild-type M. thermophila endoglucanase.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: XIYUN ZHANG, SACHIN PATIL, JIE YANG, ISH KUMAR DHAWAN
  • Publication number: 20150140572
    Abstract: The present invention relates to a composition having the activity of degrading the cell wall of a Mycobacterium species comprising: (a) a first fusion protein including (i) a domain with a first enzymatic activity, the enzymatic activity being at least one or more of the following: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetylmuramoyl-L-alanine amidase, L-alanoyl-D-glutamate (LD) endopeptidase, c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase, D-Ala-m-DAP (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase, (ii) at least one peptide stretch fused to the N- or C-terminus of the domain with the first enzymatic activity; and (iii) a protein transduction domain (PTD) being at the N- or C-terminus of the first fusion protein; and (b) a second fusion protein including (i) a domain with a second enzymatic activity, the enzymatic activity being at least one or more of the following: lipolytic activity, cutinase, mycolarabinogalactanesterase, or alpha/beta hy
    Type: Application
    Filed: July 1, 2013
    Publication date: May 21, 2015
    Inventors: Stefan Miller, Robert Andreas Fischer
  • Publication number: 20150139975
    Abstract: The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Christoph SCHMIDT, Paul N. BARLOW, Anna RICHARDS
  • Publication number: 20150140574
    Abstract: A modified polynucleotide has a different base sequence in at least one codon from a wild-type base sequence encoding a horseradish peroxidase polypeptide. The usage frequency of the modified codon of the polynucleotide corresponds to the codon usage frequencies of three filamentous fungal species in Humicola, Aspergillus, and Trichoderma. The polynucleotide is capable of expressing the polypeptide to be encoded in a filamentous fungus.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Applicant: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Fumikazu Yokoyama, Kaoru Okakura, Atsushi Inoue, Koichiro Murashima, Toshiaki Nagasato, Koji Yanai, Akitaka Nakane
  • Publication number: 20150140588
    Abstract: The present invention relates to variants with improved activity in an amide-bond reaction. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: July 3, 2012
    Publication date: May 21, 2015
    Applicant: Novozymes A/S
    Inventors: Werner Besenmatter, Allan Svendsen
  • Publication number: 20150140636
    Abstract: The invention provides a mutant hydrolase protein with enhanced kinetics and functional expression, as well as polynucleotides encoding the mutant proteins and methods of using the polynucleotides and mutant proteins.
    Type: Application
    Filed: May 22, 2014
    Publication date: May 21, 2015
    Applicant: Promega Corporation
    Inventors: Aldis Darzins, Lance P. Encell, Rachel Friedman Ohana, Paul Otto, Michael R. Slater, Gediminas Vidugiris, Keith V. Wood, Monika G. Wood, Kate Qin Zhao, Kris Zimmerman
  • Patent number: 9034598
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: May 19, 2015
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
  • Patent number: 9034608
    Abstract: The invention relates to a polypeptide having a mutation at one or more position corresponding to T219 of SEQ ID NO: 55, wherein the polypeptide has at least 50% sequence identity with SEQ ID NO: 55, and wherein the polypeptide has permease activity.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: May 19, 2015
    Assignee: DSM IP ASSETS, B.V.
    Inventors: Hendrik Wouter Wisselink, Antonius Jeroen Adriaan Van Maris, Jacobus Thomas Pronk, Paul Klaassen, Rene Marcel De Jong